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Background/aim: To evaluate salivary antioxidant defense markers, their correlation with salivary glucose, and glycemic status in type
II diabetes mellitus (DM).
Materials and methods: The study included 53 diabetic patients and 40 healthy subjects. Salivary glucose, blood glucose, and uric acid
(UA) were determined by specific enzymatic methods. Total antioxidant activity (AOA), glutathione (GSH), catalase (CAT), superoxide
dismutase (SOD), and total protein were determined spectrophotometrically.
Results: Salivary UA (3.12 vs. 1.89 mg/dL), GSH (47 vs. 11.92 µg/mL), and total protein (375.12 vs. 202.23 mg/dL) were significantly
higher (P < 0.001; r = 0.455, 0.735, 0.498 respectively) and AOA (653.1 vs. 897.3 µmol/L) was significantly lower in the DM group (P
< 0.001, r = –0.431) compared to healthy controls. Among the antioxidant enzymes, CAT was significantly lower (1214 vs. 9468.9 kat)
in the DM group (P < 0.001, r = –0.886). Spearman correlation analyses within the diabetic group showed a strong positive association
between salivary glucose and blood glucose (P < 0.001, r = 0.9), salivary glucose and GSH, and salivary glucose and UA. Salivary glucose
showed a negative correlation with AOA and CAT (P = 0.008, r = –0.447) in the diabetic group.
Conclusion: Findings of this study, showing a strong correlation between salivary glucose and blood glucose as well as changes in
antioxidant components in the DM group, suggest that saliva can be used for the diagnosis and management of DM.
Key words: Antioxidant activity, catalase, diabetes mellitus, glutathione, oxidative stress, saliva, superoxide dismutase, uric acid

1. Introduction
Diabetes mellitus (DM), a chronic endocrine metabolic
disorder, has become a worldwide epidemic affecting both
developing and developed countries. The global incidence
of DM was 366 million cases in 2011. In India alone there
were around 61.3 million cases and it is predicted that this
may increase to 101.2 million by 2030 (1). This suggests
that its diagnosis and management will become one of the
major health challenges of the 21st century. An alternate
simple approach for detection and routine monitoring of
glucose and other related parameters of DM are the need of
the hour. Recently, the use of saliva as an investigative tool
for disease processes and disorders has begun attracting
wide attention (2). Studies have explored the diagnostic
potential of saliva in cardiovascular diseases, autoimmune
disorders, cancer, oral conditions, etc. (3). Collection of
saliva is noninvasive and requires minimal expertise.
DM is characterized by chronic hyperglycemia, a
result of defects in insulin secretion and/or insulin action
* Correspondence: bindhupradip@yahoo.co.in

that cause disturbances in carbohydrate, fat, and protein
metabolism (4). There are many reports on the increased
production of free radicals leading to oxidative stress
in DM, which plays an important role in intensifying
DM-associated complications such as retinopathy,
nephropathy, etc. (4,5). Antioxidant defense mechanisms
of the body work towards minimizing this damage. The
human antioxidant system comprises 2 major groups,
enzymatic and nonenzymatic. Key enzymatic antioxidants
include catalase (CAT), superoxide dismutase (SOD),
and glutathione peroxidase. SOD is an oxidoreductase
that catalyzes dismutation of highly reactive superoxide
radicals (O2–.) to O2 and H2O2, the latter being subsequently
decomposed to harmless H2O and O2 by CAT (6,7).
Nonenzymatic antioxidants are many and include
macromolecules such as albumin, ceruloplasmin, and
ferritin as well as low-molecular-weight molecules like
ascorbic acid, reduced glutathione (GSH), uric acid (UA),
and bilirubin. All of these act synergistically to maintain
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or reestablish redox homeostasis. Total antioxidant
activity (AOA) is a measure of nonenzymatic antioxidants.
Several methods have been developed to assess the AOA
of human serum or plasma because of the difficulty in
measuring each antioxidant component separately (8). The
measured AOA of a sample depends on the methodology
and the free radical generator or oxidant used in the
measurement (8–10). An assessment of a few individual
antioxidant parameters and AOA in healthy subjects and
in controlled and uncontrolled DM cases may help in its
better management.
Accumulating data on sialochemistry show that saliva
reflects human plasma/serum biomolecular composition
associated with DM and hence the systemic condition
(2). However, contradicting results from earlier studies of
DM present a pressing need for the reevaluation of such
changes in salivary components. The purpose of this study
was to investigate the feasibility of a noninvasive approach
by using saliva for routine monitoring of glucose in DM as
well as antioxidant status in controlled and uncontrolled
DM cases as compared to healthy subjects.
2. Materials and methods
This study was conducted at the Center for Post Graduate
Studies, Jain University, Bangalore, India, for a period of
1 year (August 2011 to August 2012). The Institutional
Ethics Committee of Bhagwan Mahaveer Jain Hospital
(Bangalore, India) approved the study protocol.
2.1. Study group
The study group included in-house diabetic patients
diagnosed by the Medical Faculty of the Endocrinology
Department of Bhagwan Mahaveer Jain Hospital,
Bangalore. Prior to subject recruitment, patients with
oral infections, inflammatory conditions, and smoking
habits were identified (with assistance from consultants/
questionnaires) and excluded from the study. Informed
consent was obtained from all participants. A thorough
clinical history was collected by means of a questionnaire.
Patients were either on insulin or oral hypoglycemic
drugs. Fasting blood glucose values of chosen DM patients
(analyzed on the same day as saliva) were collected from the
hospital registry. Based on the glucose values, these cases
(n = 53) were divided into patients with controlled DM, n
= 27 (fasting blood glucose of <140 mg/dL) and patients
with uncontrolled DM, n = 26 (fasting blood glucose of
≥140 mg/dL), to form 2 groups (11). The average duration
of disease was 8.73 ± 7.29 years, excluding 2 patients that
were >30 years. The third group was a control group (n
= 40) and comprised healthy age- and sex-matched
nondiabetic subjects with blood glucose within normal
limits (Table 1). Considering the number of parameters
assayed for each sample, methods used for data collection,
and the duration of the study, a sample size large enough to
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be an accurate representative of the population to achieve
significant results and control errors was calculated.
2.2. Sample collection and preparation
Unstimulated fasting saliva from patient and control
groups was collected between 0700 and 0800 hours by
expectoration method (12,13). Subjects were asked to
rinse their mouth thoroughly with water, bend their heads
forward, and allow saliva to flow into an ice-chilled sterile
polypropylene tube. The tubes were brought immediately
to the laboratory from the collection site in chilled
conditions. Saliva samples were checked for blood and
phlegm and rejected if found to be contaminated. This
was followed by centrifugation at 4000 rpm for 15 min
to remove any particulate matter. The supernatant was
freeze-preserved or immediately used for analysis. Fasting
blood samples from patients were collected on the same
day as saliva collection by standard venipuncture by the
hospital attendant and blood glucose was estimated in the
hospital laboratory. These results were collected from the
hospital documents. Some of the healthy volunteers were
also asked to have their fasting blood glucose analyzed on
the same day as saliva collection.
2.3. Chemicals
All chemicals were procured from HiMedia (Mumbai,
India) and Merck (Bangalore, India). Kits for glucose,
protein and UA assays were procured from Accurex
Biomedical Pvt. Ltd. (Thane, India). All chemicals were of
analytical grade.
2.4. Analysis of physical characteristics
The pH of saliva samples was measured by dipping pH
strips into them and comparing the color change with
the standard color bar provided. Volume and froth
were measured by comparing the collection tube with a
precalibrated tube and reported in milliliters. Salivary flow
rate (volume of saliva secreted per minute) was obtained
by dividing the total volume of saliva in the container
with duration of collection and reported as milliliters per
minute.
2.5. Salivary enzymatic antioxidants
CAT activity was measured by Sinha’s method (14).
Estimation of SOD was carried out based on Kakkar et al.’s
method (15).
2.6. Salivary nonenzymatic parameters
Total AOA assay was carried out according to Koracevic et
al. (9). GSH was measured according to Ellman’s method
with slight modification (16), wherein to eliminate saliva
turbidity contribution to the absorbance values, an
internal control was prepared for every sample assayed.
UA was assayed using the Infinite Uric Acid Liquid Kit
(Accurex Biomedical). Glucose was assayed using the
Eco-Pak Glucose Kit (Accurex Biomedical). Total protein
was determined by the biuret method using the Autozyme
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Total Protein Biuret Kit (Accurex Biomedical). When using
the commercial kits to quantify salivary UA, glucose, and
total protein, the volume of sample used was appropriately
increased so that the concentration was closer to the
standard provided by these kits.
2.7. Statistical analysis
Statistical analysis was performed using GraphPad
Prism 5 (GraphPad Software, Inc., San Diego, CA, USA)
(17). Analysis of variance (ANOVA) and the Spearman
correlation test were used. P < 0.05 was considered
significant.
3. Results
Samples from 93 subjects were included in the study, out
of which 53 were diabetic patients and 40 were healthy
controls. The diabetic patients were divided into 2 groups:
controlled DM (fasting blood glucose of <140 mg/dL) and
uncontrolled DM (fasting blood glucose of ≥140 mg/dL)
(Table 1).
A significant increase in the mean salivary glucose
concentration (P < 0.001) was observed in the diabetic
group when compared to healthy controls. SOD and CAT,
major antioxidant enzymes, showed different responses.
SOD showed a marginally higher activity in diabetic cases,
with no difference in the subgroups. However, a drastic
reduction in CAT activity was seen in diabetic samples,
with a 7.11 and 8.66 times reduction in the controlled and
uncontrolled groups, respectively (Table 2).
The AOA was found to be lower in diabetic patients,
with maximum reduction observed in the uncontrolled
group. GSH level was higher in diabetic (both controlled
and uncontrolled) patients. Mean UA was approximately
1.7 times higher in diabetic patients than in healthy
controls. Salivary total protein was found to be almost 2

times higher in the uncontrolled group and about 1.5 times
higher in the controlled DM group (mean: approximately
1.8 times). Table 2 compares the mean values of the salivary
parameters analyzed.
3.1. Spearman correlation analysis
In order to determine whether the differences observed
could be linked to glycemia, the parameters recorded in the
diabetic group were compared to salivary glucose levels.
Fasting salivary glucose showed strong positive correlation
with fasting blood glucose (all diabetic patients: r = 0.9, P
< 0.001; controlled cases: r = 0.9, P < 0.001; uncontrolled
cases: r = 0.922, P < 0.001). Association between UA and
salivary glucose in the diabetic group was found to be
positive. AOA showed a significant negative correlation
with salivary glucose mainly because of the uncontrolled
diabetic category. GSH showed positive correlation with
salivary glucose. Among the endogenous enzymes, CAT
showed a significant negative correlation with salivary
glucose in the diabetic group, with the uncontrolled
category exhibiting a higher contribution. SOD showed a
negative correlation with salivary glucose. Tables 3 and 4
show results of Spearman correlation analyses.
Flow rate and pH decreased with increase in
salivary glucose content. Salivary total protein was also
significantly higher in diabetic patients who suffered from
other pathological conditions (hypertension, cardiacrelated ailments, etc.) in addition to DM. An increase in
froth and a marginally low salivary flow rate along with pH
were other significant observations in the diabetic group.
Other associated observations included male diabetic
patients showing a significantly high GSH level compared
to females. With age, CAT activity and AOA showed
a negative association; however, there was a positive
association with GSH.

Table 1. Study group details.
Group

Number

Age, years

Fasting blood glucose,
mean ± SD, mg/dL

Healthy controls
Males (18)
Females (22)

40

53.50 ± 10.67
(34–71)

86.30 ± 4.8
(80–102)

Diabetic patients
Males (32)
Females (21)

53

61.96 ± 13.5
(33–84)

160.64 ± 73
(80–340)

Diabetic patients (controlled cases)

27

63.29 ± 14.3
(33–84)

109 ± 15.9
(80–140)

Diabetic patients (uncontrolled cases)

26

60.63 ± 13
(43–84)

211.85 ± 70.62
(140–340)

Controlled DM: blood glucose of <140 mg/dL; uncontrolled DM: blood glucose of ≥140 mg/dL.
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Table 2. Mean values of salivary parameters analyzed.
Mean (SE)
S.
no.

Parameter

Diabetic subjects
All diabetic patients

Uncontrolled cases

Controlled cases

Healthy controls

P-value
(r-value) between
healthy subjects and all
diabetic patients

1

Fasting glucose (mg/dL)

161.07 (10)

214.69 (14.1)

109.44 (3.1)

81.60 (0.5)

<0.001 (0.580)

2

UA (mg/dL)

3.12 (0.21)

3.26 (0.3)

3.03 (0.2)

1.89 (0.1)

<0.001 (0.455)

3

GSH (µg/mL)

47 (2.8)

49.9 (2.3)

44.8 (4.2)

11.92 (1.1)

<0.001 (0.735)

4

AOA (µmol uric acid eq/L)

653.10 (45)

542.86 (51)

759.30 (68)

897.30 (16.2)

<0.001 (–0.431)

5

SOD (U/mL)

0.26 (0.01)

0.26 (0.01)

0.26 (0.01)

0.23 (0.02)

>0.05 (0.190)

6

CAT (kat)

1214 (68)

1092.22 (61.1)

1330.37 (116)

9468.90 (515)

<0.001 (–0.886)

7

Salivary glucose (mg/dL)

5.83 (0.5)

8.34 (0.8)

3.41 (0.1)

2.07 (0.1)

<0.001 (0.515)

8

Total protein (mg/dL)

375.12 (26)

407.80 (40.6)

346 (32.3)

202.23 (14.7)

<0.001 (0.498)

Controlled DM: blood glucose of <140 mg/dL; uncontrolled DM: blood glucose of ≥140 mg/dL; P < 0.05 is considered significant. SE: standard error of
mean.

Table 3. Correlative analysis of salivary glucose with various parameters in type II diabetic patients.
Correlations
B. glucose–S. glucose

UA–S. glucose

GSH–S. glucose

CAT–S. glucose

SOD–S. glucose

All diabetic patients

Uncontrolled cases

Controlled cases

r-value

0.9*

0.922*

0.9*

P-value

<0.001

<0.001

>0.001

r-value

0.258

0.409

0.038

P-value

0.079

0.072

0.847

r-value

0.003

–0.217

0.130

P-value

0.97

0.318

0.533

r-value

–0.447*

P-value

0.008

<0.001

0.544

r-value

–0.428*

–0.458

0.181

P-value

0.004

0.018

0.364

–0.934*

0.122

*: Significant, S: salivary, B: blood. Controlled DM: blood glucose of <140 mg/dL; uncontrolled DM: blood glucose of
≥140 mg/dL.
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Table 4. Correlations observed between various salivary parameters studied in the diabetic group.
Correlation

Positive correlation

Negative correlation

Parameters

r-value

P-value

CAT–AOA

0.437

<0.001

TP–UA

0.393

<0.001

TP–GSH

0.356

<0.001

GSH–UA

0.244

0.043

CAT–GSH

–0.654

<0.001

CAT–TP

–0.489

<0.001

CAT–UA

–0.471

<0.001

AOA–GSH

–0.440

<0.001

CAT–SOD

–0.241

<0.001

AOA–TP

–0.241

0.024

4. Discussion
The present study demonstrates that glucose and
antioxidant levels in saliva from diabetic patients exhibit
significant differences compared to control samples.
There was a remarkable increase in fasting salivary
glucose levels in the diabetic group. Another significant
observation was a parallel increase in fasting salivary
glucose with fasting blood glucose levels, which coincides
with previous observations made by Hegde et al. (18). To
analyze the potential of saliva in reflecting the glycemic
picture, correlation analysis between salivary glucose
and blood glucose levels was carried out. A value of P <
0.001 supports the suitability of saliva as a substitute for
blood for monitoring the glycemic status (19). There are
also a few reports contradicting the above observations
(11,20,21).
CAT exhibited a marked reduction in its activity,
contributing less to the removal of H2O2. Assessment of
salivary CAT activity in DM is sparse. However, increased
CAT has been reported in experimental rats under induced
diabetic conditions (22–24). Negative correlation of CAT
with salivary glucose and contribution by uncontrolled
DM in this correlation may indicate its prognostic potential
in this disorder. Only a marginal increase in SOD activity
was observed in the diabetic group, as also observed by AlRawi (17). This marginal increase could be to combat the
excess O2–. possibly produced in this disorder.
UA is a strong antioxidant in a hydrophilic environment
(25). An increase in UA concentration, which corroborates
with earlier findings (17), was observed in the saliva of
diabetic patients in the present study. It showed a positive
correlation with salivary glucose. Uncontrolled diabetic
patients had higher levels, suggesting its association with
severity of this disease. This supports the compensatory

antioxidant defense by UA in saliva. However, the defense
role of UA is controversial. Recently it was shown that
under selected circumstances, the original antioxidant
properties of UA paradoxically become prooxidant (9). It
is worth noting that hyperuricemia has been found to be
associated with obesity, metabolic syndrome, and insulin
resistance and consequently with type 2 DM (26).
GSH was found to be present in enhanced quantities
in diabetic individuals in this study, whereas work by Savu
et al. and Memisogullari et al. reported a decrease in GSH
(27,28). Enhanced levels of GSH and UA may possibly be
a compensatory response to tackle O2–. load through free
radical scavenging. Reduction in CAT activity could also
be a predisposing factor for the observed enhanced GSH
level. This can be further substantiated by studying the
contribution of GSH under such circumstances.
Total AOA decreased with increase in salivary glucose
in the current study. However, a few other reports
suggested an increase in AOA in diabetic saliva (18,29).
The perplexing observation in this study was a decrease
in AOA in spite of elevated levels of UA and GSH in
DM. The measured AOA of a sample depends on which
method is used in the measurement (8,14). The current
study used a method that recommends UA as a standard
(9). GSH response to this method is poor. Mean salivary
UA concentration in healthy volunteers was 1.89 mg/dL
(112 µmol/L), which corresponds to 12.48% of total AOA
(897.31 µmol/L). The rest of the measured AOA appeared
to be the result of other antioxidant salivary components.
In the diabetic group, mean salivary UA concentration was
3.12 mg/dL (180 µmol/L), which represented 27.56% of the
total AOA (653.13 µmol/L). Thus, even with an increase
in UA, changes in other salivary antioxidant components
might have led to the decrease in total AOA.
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Salivary total protein level was found to be increased in
the diabetic group in comparison with that of the controls,
as repeatedly reported in various earlier studies (30).
Protein antioxidants such as albumin have been recently
reported to be important contributors to antioxidant
plasmatic barriers (31). However, its role at the salivary
level still needs to be probed. The reflection of glycemic
status in saliva remains one of the significant observations
of the study. Taken together with the observed antioxidant
biochemical variations in saliva, this study brings
substantial insight into the pathogenesis and evolution of

type II diabetes. Whether such alterations predispose one
to the development of associated systemic complications
remains to be addressed by a follow-up study.
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